CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

‒ Q4 2024 Net Revenue of $31.2mm; 2024 Net Revenue of$43.5mm ‒ ‒ Q4 Net Income of $13.5mm and Adjusted EBITDA of$15.3mm ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the fourth quarter and full year ended December 31, 2024 a ...